s20098 has been researched along with Brain Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ayar, A; Bulmus, O; Canpolat, S; Kacar, E; Kelestimur, H; Ozcan, M; Ozcan, S; Serhatlioglu, I; Tekin, S; Tektemur, A; Ulker, N | 1 |
| Gressens, P; Husson, I; Mocaer, E; Sarkozy, G; Schwendimann, L; Spedding, M; Vamecq, J | 1 |
2 other study(ies) available for s20098 and Brain Disorders
| Article | Year |
|---|---|
Agomelatine pretreatment prevents development of hyperglycemia and hypoinsulinemia in streptozotocin-induced diabetes in mice.
Topics: Acetamides; Animals; Anti-Inflammatory Agents; Antioxidants; Biomarkers; Blood Glucose; Brain; Brain Diseases; Cell Survival; Cells, Cultured; Diabetes Mellitus, Experimental; Ganglia, Spinal; Hyperglycemia; Hypoglycemic Agents; Inflammation Mediators; Insulin; Interleukin-1beta; Male; Mice, Inbred BALB C; Neuroprotective Agents; Rats, Wistar; Receptors, Neurokinin-1; Streptozocin | 2019 |
Agomelatine, a melatonin receptor agonist with 5-HT(2C) receptor antagonist properties, protects the developing murine white matter against excitotoxicity.
Topics: Acetamides; Animals; Brain; Brain Diseases; Excitatory Amino Acid Agonists; Ibotenic Acid; Melatonin; Mice; Neuroprotective Agents; Receptor, Serotonin, 5-HT2C; Receptors, Melatonin; Serotonin Antagonists; Tryptamines | 2008 |